At 12:30 IST, the barometer index, the S&P BSE Sensex shed 45.09 points or 0.05% to 85,791.03. The Nifty 50 index added 22.15 points or 0.08% to 26,238.20.
The Sensex and Nifty clocked an all-time high of 85,978.25 and 26,277.35, respectively in mid morning trade.
In the broader market, the S&P BSE Mid-Cap index rose 0.22% and the S&P BSE Small-Cap index added 0.34%.
The market breadth was strong. On the BSE, 2,175 shares rose and 1,641 shares fell. A total of 142 shares were unchanged.
Derivatives:
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, tumbled 4.82% to 12.13. The Nifty 31 October 2024 futures were trading at 26,368, at a premium of 129.8 points as compared with the spot at 26,238.20.
The Nifty option chain for the 31 October 2024 expiry showed maximum Call OI of 65 lakh contracts at the 27,000 strike price. Maximum Put OI of 47.6 lakh contracts were seen at 26,000 strike price.
Buzzing Index:
The Nifty Oil & Gas rose 0.95% to 12,945.15. The index advanced 4.27% in the sixth consecutive trading session.
Bharat Petroleum Corporation (up 3.87%), Gujarat State Petronet (up 3.57%), Hindustan Petroleum Corporation (up 2%), Gujarat Gas (up 1.6%), Castrol India (up 1.57%), Indian Oil Corporation (up 1.54%), Petronet LNG (up 1.29%), GAIL (India) (up 1.26%), Indraprastha Gas (up 0.86%) and Adani Total Gas (up 0.44%) edged higher.
Stocks in Spotlight :
Indian Bank rose 0.51%. The bank said that its board, at the meeting held on Thursday (26 September 2024) has approved for raising additional long term infrastructure bonds aggregating up to Rs 5000 crore, in one or more tranches.
Genesys International Corporation added 1.10% after the company has received two new contracts from NEOM and the Saudi Geological Survey Authority to adopt geospatial technology for infrastructural development in Saudi Arabia.
Rail Vikas Nigam (RVNL) gained 1.19% after the company announced that it has signed memorandum of understanding (MoU) with Engineers India (EIL) to explore global business opportunities.
Biocon fell 0.43%. The company said that it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialize its GLP-1 products for treating diabetes and chronic weight management, in select countries of the Middle East.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
